Literature DB >> 22974781

Treatment of lung cancer.

Shirish M Gadgeel1, Suresh S Ramalingam, Gregory P Kalemkerian.   

Abstract

Lung cancer is a heterogenous disease with 2 main subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Early-stage NSCLC is managed primarily by surgical resection, with adjuvant chemotherapy for selected patients with stage IB, II, and III disease. Patients with locally advanced stage III NSCLC are usually treated with combined modality therapy. Advanced NSCLC remains an incurable disease. Further advances will rely on improvements in understanding of the molecular events driving the malignant phenotype and the development of novel, targeted therapeutic strategies.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22974781     DOI: 10.1016/j.rcl.2012.06.003

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  32 in total

1.  Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.

Authors:  Joshua H Finkle; Stephanie Y Jo; Mark K Ferguson; Hai-Yan Liu; Chenpeng Zhang; Xuee Zhu; Cindy Yuan; Yonglin Pu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-07       Impact factor: 9.236

2.  A new PET/CT volumetric prognostic index for non-small cell lung cancer.

Authors:  Hao Zhang; Kristen Wroblewski; Yulei Jiang; Bill C Penney; Daniel Appelbaum; Cassie A Simon; Ravi Salgia; Yonglin Pu
Journal:  Lung Cancer       Date:  2015-04-09       Impact factor: 5.705

3.  Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma.

Authors:  Ming Li; Chuanying Li; Li Ke; Mali Zhan; Min Cheng
Journal:  Oncol Lett       Date:  2018-10-02       Impact factor: 2.967

4.  Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab.

Authors:  Nicholas G Zaorsky; Yunguang Sun; Zixuan Wang; Joshua Palmer; Paolo M Fortina; Charalambos Solomides; Maria Werner-Wasik; Adam P Dicker; Rita Axelrod; Barbara Campling; Nathaniel Evans; Scott Cowan; Bo Lu
Journal:  Cancer Biol Ther       Date:  2013-08-02       Impact factor: 4.742

Review 5.  The utilisation of convolutional neural networks in detecting pulmonary nodules: a review.

Authors:  Andrew Murphy; Matthew Skalski; Frank Gaillard
Journal:  Br J Radiol       Date:  2018-06-19       Impact factor: 3.039

6.  Evaluation of role of Notch3 signaling pathway in human lung cancer cells.

Authors:  Wael Abdo Hassan; Ryoji Yoshida; Shinji Kudoh; Yamato Motooka; Takaaki Ito
Journal:  J Cancer Res Clin Oncol       Date:  2016-02-02       Impact factor: 4.553

7.  Clinical value of microRNA-23a upregulation in non-small cell lung cancer.

Authors:  Wei-Qing Qu; Lei Liu; Zhe Yu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

8.  Preoperative D-dimer level is an independent prognostic factor for non-small cell lung cancer after surgical resection: a systematic review and meta-analysis.

Authors:  Han-Yu Deng; Xi Zheng; Rui Jiang; Rui-Lan Wang; Jie Zhou; Xiao-Ming Qiu
Journal:  Ann Transl Med       Date:  2019-08

9.  Induction chemotherapy for T3N0M0 non-small-cell lung cancer increases the rate of complete resection but does not confer improved survival.

Authors:  Kevin L Anderson; Michael S Mulvihill; Babatunde A Yerokun; Paul J Speicher; Thomas A D'Amico; Betty C Tong; Mark F Berry; Matthew G Hartwig
Journal:  Eur J Cardiothorac Surg       Date:  2017-08-01       Impact factor: 4.191

10.  Bioreducible Poly(Amino Ethers) Based mTOR siRNA Delivery for Lung Cancer.

Authors:  Nishant S Gandhi; Sudhakar Godeshala; Dana-Lynn T Koomoa-Lange; Bhavani Miryala; Kaushal Rege; Mahavir B Chougule
Journal:  Pharm Res       Date:  2018-08-13       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.